XAIR
Beyond Air, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$3.09
+0.32%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.07
From 52W high−94.28%
Volume38772.00
Market cap$3.04M
P/E (TTM)—
P/S (TTM)0.4x
Div yield—
Key dataSep 18, 2026
Open
$3.07
From 52W high
−94.28%
Volume
38772.00
Market cap
$3.04M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
32.5
MomentumView details →
1D Return
+0.32%
YTD Return
−77.89%
SummaryUpdated Jun 1, 2026
Beyond Air, Inc. (NASDAQ:XAIR) is a commercial-stage medical device and biopharmaceutical company founded in 2018 and based in Garden City, New York. The company was formerly known as AIT Therapeutics, Inc. before changing its name in June 2019. Beyond Air specializes in developing nitric oxide-based therapeutic solutions, with its flagship product being the LungFit platform - a revolutionary nitric oxide generator and delivery system that creates therapeutic nitric oxide from ambient air rather than requiring traditional gas cylinders.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration granted Breakthrough Device Designation to Beyond Air's LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease.20d agoBeyond Air entered a definitive agreement to sell its NeuroNOS stake to UNIVO Pharmaceutical Industries in exchange for equity and milestone payments.26d ago